Sarepta Therapeutics Inc.

Company Overview

Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company that develops RNA-targeted therapeutics and gene therapy products for the treatment of rare diseases. It focuses on therapeutic indications, including Duchenne muscular dystrophy, limb-girdle muscular dystrophies, other neuromuscular disorders such as facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1, as well as central nervous system disorders.

Sarepta Therapeutics Inc. has proprietary products for the development of RNA therapeutics, gene therapy and gene editing. It has partnered with numerous companies, including Roche, Arrowhead Pharmaceuticals and BioMarin, for the development of its products.

Financial Highlights (FY 2025)

Company's Business Segments

• Product : EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS.
• Collaboration and other : Collaboration and other revenues primarily relate to collaboration arrangement with Roche.